0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Granulomatous Disease (CGD) Treatment Market Research Report 2024
Published Date: July 2024
|
Report Code: QYRE-Auto-34O12931
Home | Market Reports | Health| Health Conditions| Skin Conditions
Global Chronic Granulomatous Disease CGD Treatment Market Research Report 2023
BUY CHAPTERS

Global Chronic Granulomatous Disease (CGD) Treatment Market Research Report 2024

Code: QYRE-Auto-34O12931
Report
July 2024
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Chronic Granulomatous Disease (CGD) Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Chronic Granulomatous Disease (CGD) Treatment Market

Chronic Granulomatous Disease (CGD) Treatment Market

The global Chronic Granulomatous Disease (CGD) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Granulomatous Disease (CGD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Granulomatous Disease (CGD) Treatment.

Report Scope

The Chronic Granulomatous Disease (CGD) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Granulomatous Disease (CGD) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Granulomatous Disease (CGD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Chronic Granulomatous Disease (CGD) Treatment Market Report

Report Metric Details
Report Name Chronic Granulomatous Disease (CGD) Treatment Market
CAGR 5%
Segment by Type
  • X-Linked Chronic Granulomatous Disease
  • Autosomal Recessive Chronic Granulomatous Disease
Segment by Application
  • Neutrophil Function Tests
  • Genetic Testing
  • Prenatal Testing
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Chronic Granulomatous Disease (CGD) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Granulomatous Disease (CGD) Treatment Market report?

Ans: The main players in the Chronic Granulomatous Disease (CGD) Treatment Market are Clinigen Group plc, Orchard Therapeutics plc2032, Horizon Therapeutics plc, ViroMed. Co. Ltd, Bellicum Pharmaceuticals, Inc, Pfizer Inc, Hoffmann-La Roche Ltd, Novartis AG, Lonza, GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson Services, Inc, Merck KGaA

What are the Application segmentation covered in the Chronic Granulomatous Disease (CGD) Treatment Market report?

Ans: The Applications covered in the Chronic Granulomatous Disease (CGD) Treatment Market report are Neutrophil Function Tests, Genetic Testing, Prenatal Testing

What are the Type segmentation covered in the Chronic Granulomatous Disease (CGD) Treatment Market report?

Ans: The Types covered in the Chronic Granulomatous Disease (CGD) Treatment Market report are X-Linked Chronic Granulomatous Disease, Autosomal Recessive Chronic Granulomatous Disease

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 X-Linked Chronic Granulomatous Disease
1.2.3 Autosomal Recessive Chronic Granulomatous Disease
1.3 Market by Application
1.3.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Neutrophil Function Tests
1.3.3 Genetic Testing
1.3.4 Prenatal Testing
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Perspective (2019-2030)
2.2 Chronic Granulomatous Disease (CGD) Treatment Growth Trends by Region
2.2.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Granulomatous Disease (CGD) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Chronic Granulomatous Disease (CGD) Treatment Market Dynamics
2.3.1 Chronic Granulomatous Disease (CGD) Treatment Industry Trends
2.3.2 Chronic Granulomatous Disease (CGD) Treatment Market Drivers
2.3.3 Chronic Granulomatous Disease (CGD) Treatment Market Challenges
2.3.4 Chronic Granulomatous Disease (CGD) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Granulomatous Disease (CGD) Treatment Players by Revenue
3.1.1 Global Top Chronic Granulomatous Disease (CGD) Treatment Players by Revenue (2019-2024)
3.1.2 Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Granulomatous Disease (CGD) Treatment Revenue
3.4 Global Chronic Granulomatous Disease (CGD) Treatment Market Concentration Ratio
3.4.1 Global Chronic Granulomatous Disease (CGD) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Granulomatous Disease (CGD) Treatment Revenue in 2023
3.5 Chronic Granulomatous Disease (CGD) Treatment Key Players Head office and Area Served
3.6 Key Players Chronic Granulomatous Disease (CGD) Treatment Product Solution and Service
3.7 Date of Enter into Chronic Granulomatous Disease (CGD) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Granulomatous Disease (CGD) Treatment Breakdown Data by Type
4.1 Global Chronic Granulomatous Disease (CGD) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Type (2025-2030)
5 Chronic Granulomatous Disease (CGD) Treatment Breakdown Data by Application
5.1 Global Chronic Granulomatous Disease (CGD) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)
6.2 North America Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024)
6.4 North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)
7.2 Europe Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024)
7.4 Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)
9.2 Latin America Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024)
9.4 Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Clinigen Group plc
11.1.1 Clinigen Group plc Company Detail
11.1.2 Clinigen Group plc Business Overview
11.1.3 Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Introduction
11.1.4 Clinigen Group plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.1.5 Clinigen Group plc Recent Development
11.2 Orchard Therapeutics plc2032
11.2.1 Orchard Therapeutics plc2032 Company Detail
11.2.2 Orchard Therapeutics plc2032 Business Overview
11.2.3 Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Introduction
11.2.4 Orchard Therapeutics plc2032 Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.2.5 Orchard Therapeutics plc2032 Recent Development
11.3 Horizon Therapeutics plc
11.3.1 Horizon Therapeutics plc Company Detail
11.3.2 Horizon Therapeutics plc Business Overview
11.3.3 Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Introduction
11.3.4 Horizon Therapeutics plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.3.5 Horizon Therapeutics plc Recent Development
11.4 ViroMed. Co. Ltd
11.4.1 ViroMed. Co. Ltd Company Detail
11.4.2 ViroMed. Co. Ltd Business Overview
11.4.3 ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Introduction
11.4.4 ViroMed. Co. Ltd Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.4.5 ViroMed. Co. Ltd Recent Development
11.5 Bellicum Pharmaceuticals, Inc
11.5.1 Bellicum Pharmaceuticals, Inc Company Detail
11.5.2 Bellicum Pharmaceuticals, Inc Business Overview
11.5.3 Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Introduction
11.5.4 Bellicum Pharmaceuticals, Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.5.5 Bellicum Pharmaceuticals, Inc Recent Development
11.6 Pfizer Inc
11.6.1 Pfizer Inc Company Detail
11.6.2 Pfizer Inc Business Overview
11.6.3 Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Introduction
11.6.4 Pfizer Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.6.5 Pfizer Inc Recent Development
11.7 Hoffmann-La Roche Ltd
11.7.1 Hoffmann-La Roche Ltd Company Detail
11.7.2 Hoffmann-La Roche Ltd Business Overview
11.7.3 Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Introduction
11.7.4 Hoffmann-La Roche Ltd Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.7.5 Hoffmann-La Roche Ltd Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Detail
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Chronic Granulomatous Disease (CGD) Treatment Introduction
11.8.4 Novartis AG Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.8.5 Novartis AG Recent Development
11.9 Lonza
11.9.1 Lonza Company Detail
11.9.2 Lonza Business Overview
11.9.3 Lonza Chronic Granulomatous Disease (CGD) Treatment Introduction
11.9.4 Lonza Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.9.5 Lonza Recent Development
11.10 GlaxoSmithKline plc
11.10.1 GlaxoSmithKline plc Company Detail
11.10.2 GlaxoSmithKline plc Business Overview
11.10.3 GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Introduction
11.10.4 GlaxoSmithKline plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.10.5 GlaxoSmithKline plc Recent Development
11.11 Eli Lilly and Company
11.11.1 Eli Lilly and Company Company Detail
11.11.2 Eli Lilly and Company Business Overview
11.11.3 Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Introduction
11.11.4 Eli Lilly and Company Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.11.5 Eli Lilly and Company Recent Development
11.12 Johnson & Johnson Services, Inc
11.12.1 Johnson & Johnson Services, Inc Company Detail
11.12.2 Johnson & Johnson Services, Inc Business Overview
11.12.3 Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Introduction
11.12.4 Johnson & Johnson Services, Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.12.5 Johnson & Johnson Services, Inc Recent Development
11.13 Merck KGaA
11.13.1 Merck KGaA Company Detail
11.13.2 Merck KGaA Business Overview
11.13.3 Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Introduction
11.13.4 Merck KGaA Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
11.13.5 Merck KGaA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of X-Linked Chronic Granulomatous Disease
    Table 3. Key Players of Autosomal Recessive Chronic Granulomatous Disease
    Table 4. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 5. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Region (2019-2024)
    Table 8. Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Region (2025-2030)
    Table 10. Chronic Granulomatous Disease (CGD) Treatment Market Trends
    Table 11. Chronic Granulomatous Disease (CGD) Treatment Market Drivers
    Table 12. Chronic Granulomatous Disease (CGD) Treatment Market Challenges
    Table 13. Chronic Granulomatous Disease (CGD) Treatment Market Restraints
    Table 14. Global Chronic Granulomatous Disease (CGD) Treatment Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Players (2019-2024)
    Table 16. Global Top Chronic Granulomatous Disease (CGD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Treatment as of 2023)
    Table 17. Ranking of Global Top Chronic Granulomatous Disease (CGD) Treatment Companies by Revenue (US$ Million) in 2023
    Table 18. Global 5 Largest Players Market Share by Chronic Granulomatous Disease (CGD) Treatment Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Chronic Granulomatous Disease (CGD) Treatment Product Solution and Service
    Table 21. Date of Enter into Chronic Granulomatous Disease (CGD) Treatment Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Type (2019-2024)
    Table 25. Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Type (2025-2030)
    Table 27. Global Chronic Granulomatous Disease (CGD) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Application (2019-2024)
    Table 29. Global Chronic Granulomatous Disease (CGD) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global Chronic Granulomatous Disease (CGD) Treatment Revenue Market Share by Application (2025-2030)
    Table 31. North America Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 32. North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 33. North America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 34. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 35. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 36. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 37. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 38. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 39. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 41. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 42. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 43. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Clinigen Group plc Company Detail
    Table 47. Clinigen Group plc Business Overview
    Table 48. Clinigen Group plc Chronic Granulomatous Disease (CGD) Treatment Product
    Table 49. Clinigen Group plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 50. Clinigen Group plc Recent Development
    Table 51. Orchard Therapeutics plc2032 Company Detail
    Table 52. Orchard Therapeutics plc2032 Business Overview
    Table 53. Orchard Therapeutics plc2032 Chronic Granulomatous Disease (CGD) Treatment Product
    Table 54. Orchard Therapeutics plc2032 Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 55. Orchard Therapeutics plc2032 Recent Development
    Table 56. Horizon Therapeutics plc Company Detail
    Table 57. Horizon Therapeutics plc Business Overview
    Table 58. Horizon Therapeutics plc Chronic Granulomatous Disease (CGD) Treatment Product
    Table 59. Horizon Therapeutics plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 60. Horizon Therapeutics plc Recent Development
    Table 61. ViroMed. Co. Ltd Company Detail
    Table 62. ViroMed. Co. Ltd Business Overview
    Table 63. ViroMed. Co. Ltd Chronic Granulomatous Disease (CGD) Treatment Product
    Table 64. ViroMed. Co. Ltd Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 65. ViroMed. Co. Ltd Recent Development
    Table 66. Bellicum Pharmaceuticals, Inc Company Detail
    Table 67. Bellicum Pharmaceuticals, Inc Business Overview
    Table 68. Bellicum Pharmaceuticals, Inc Chronic Granulomatous Disease (CGD) Treatment Product
    Table 69. Bellicum Pharmaceuticals, Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 70. Bellicum Pharmaceuticals, Inc Recent Development
    Table 71. Pfizer Inc Company Detail
    Table 72. Pfizer Inc Business Overview
    Table 73. Pfizer Inc Chronic Granulomatous Disease (CGD) Treatment Product
    Table 74. Pfizer Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 75. Pfizer Inc Recent Development
    Table 76. Hoffmann-La Roche Ltd Company Detail
    Table 77. Hoffmann-La Roche Ltd Business Overview
    Table 78. Hoffmann-La Roche Ltd Chronic Granulomatous Disease (CGD) Treatment Product
    Table 79. Hoffmann-La Roche Ltd Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 80. Hoffmann-La Roche Ltd Recent Development
    Table 81. Novartis AG Company Detail
    Table 82. Novartis AG Business Overview
    Table 83. Novartis AG Chronic Granulomatous Disease (CGD) Treatment Product
    Table 84. Novartis AG Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 85. Novartis AG Recent Development
    Table 86. Lonza Company Detail
    Table 87. Lonza Business Overview
    Table 88. Lonza Chronic Granulomatous Disease (CGD) Treatment Product
    Table 89. Lonza Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 90. Lonza Recent Development
    Table 91. GlaxoSmithKline plc Company Detail
    Table 92. GlaxoSmithKline plc Business Overview
    Table 93. GlaxoSmithKline plc Chronic Granulomatous Disease (CGD) Treatment Product
    Table 94. GlaxoSmithKline plc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 95. GlaxoSmithKline plc Recent Development
    Table 96. Eli Lilly and Company Company Detail
    Table 97. Eli Lilly and Company Business Overview
    Table 98. Eli Lilly and Company Chronic Granulomatous Disease (CGD) Treatment Product
    Table 99. Eli Lilly and Company Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 100. Eli Lilly and Company Recent Development
    Table 101. Johnson & Johnson Services, Inc Company Detail
    Table 102. Johnson & Johnson Services, Inc Business Overview
    Table 103. Johnson & Johnson Services, Inc Chronic Granulomatous Disease (CGD) Treatment Product
    Table 104. Johnson & Johnson Services, Inc Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 105. Johnson & Johnson Services, Inc Recent Development
    Table 106. Merck KGaA Company Detail
    Table 107. Merck KGaA Business Overview
    Table 108. Merck KGaA Chronic Granulomatous Disease (CGD) Treatment Product
    Table 109. Merck KGaA Revenue in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024) & (US$ Million)
    Table 110. Merck KGaA Recent Development
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Type: 2023 VS 2030
    Figure 3. X-Linked Chronic Granulomatous Disease Features
    Figure 4. Autosomal Recessive Chronic Granulomatous Disease Features
    Figure 5. Global Chronic Granulomatous Disease (CGD) Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 6. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Application: 2023 VS 2030
    Figure 7. Neutrophil Function Tests Case Studies
    Figure 8. Genetic Testing Case Studies
    Figure 9. Prenatal Testing Case Studies
    Figure 10. Chronic Granulomatous Disease (CGD) Treatment Report Years Considered
    Figure 11. Global Chronic Granulomatous Disease (CGD) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Chronic Granulomatous Disease (CGD) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Region: 2023 VS 2030
    Figure 14. Global Chronic Granulomatous Disease (CGD) Treatment Market Share by Players in 2023
    Figure 15. Global Top Chronic Granulomatous Disease (CGD) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Granulomatous Disease (CGD) Treatment as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Chronic Granulomatous Disease (CGD) Treatment Revenue in 2023
    Figure 17. North America Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Chronic Granulomatous Disease (CGD) Treatment Market Share by Country (2019-2030)
    Figure 19. United States Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. Canada Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Europe Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Europe Chronic Granulomatous Disease (CGD) Treatment Market Share by Country (2019-2030)
    Figure 23. Germany Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. France Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. U.K. Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Italy Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Russia Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Nordic Countries Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Asia-Pacific Chronic Granulomatous Disease (CGD) Treatment Market Share by Region (2019-2030)
    Figure 31. China Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Japan Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. South Korea Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Southeast Asia Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. India Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Australia Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Latin America Chronic Granulomatous Disease (CGD) Treatment Market Share by Country (2019-2030)
    Figure 39. Mexico Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Brazil Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa Chronic Granulomatous Disease (CGD) Treatment Market Share by Country (2019-2030)
    Figure 43. Turkey Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Saudi Arabia Chronic Granulomatous Disease (CGD) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Clinigen Group plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 46. Orchard Therapeutics plc2032 Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 47. Horizon Therapeutics plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 48. ViroMed. Co. Ltd Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 49. Bellicum Pharmaceuticals, Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 50. Pfizer Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 51. Hoffmann-La Roche Ltd Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 52. Novartis AG Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 53. Lonza Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 54. GlaxoSmithKline plc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 55. Eli Lilly and Company Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 56. Johnson & Johnson Services, Inc Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 57. Merck KGaA Revenue Growth Rate in Chronic Granulomatous Disease (CGD) Treatment Business (2019-2024)
    Figure 58. Bottom-up and Top-down Approaches for This Report
    Figure 59. Data Triangulation
    Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Scar Silicone Gels Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-12F15742
Wed Aug 21 00:00:00 UTC 2024

Add to Cart

Global Varicose Vein Closure System Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-1R18103
Mon Aug 19 00:00:00 UTC 2024

Add to Cart

Global Moderate to Severe Atopic Dermatitis Treatment Drugs Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-7H18248
Fri Aug 16 00:00:00 UTC 2024

Add to Cart

Global Cellulitis Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-38X14265
Wed Aug 14 00:00:00 UTC 2024

Add to Cart